|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
US20020142000A1
(en)
|
1999-01-15 |
2002-10-03 |
Digan Mary Ellen |
Anti-CD3 immunotoxins and therapeutic uses therefor
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
JP3535868B2
(ja)
|
2000-10-05 |
2004-06-07 |
松下電器産業株式会社 |
判定レベル設定方法、およびデータ受信装置
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US20020165360A1
(en)
|
2000-11-30 |
2002-11-07 |
Junghans Richard P. |
Chimeric effector cell receptors against carcinoembryonic antigen
|
|
NZ571596A
(en)
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
CA2471551C
(en)
|
2001-12-27 |
2014-09-30 |
Glycofi, Inc. |
Methods to engineer mammalian-type carbohydrate structures
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
|
CA2481658A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to fcy receptor iiia
|
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
|
CA2481925A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Therapeutic agent for patients having human fc.gamma.riiia
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
US7232888B2
(en)
|
2002-07-01 |
2007-06-19 |
Massachusetts Institute Of Technology |
Antibodies against tumor surface antigens
|
|
EP1539966B1
(en)
|
2002-09-12 |
2010-06-30 |
Greenovation Biotech GmbH |
Protein production method
|
|
WO2004057002A2
(en)
|
2002-12-20 |
2004-07-08 |
Greenovation Biotech Gmbh |
Production of heterologous glycosylated proteins in bryophyte cells
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
EP2248892B1
(en)
|
2003-01-22 |
2015-04-22 |
Roche Glycart AG |
Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
|
|
AU2003265522A1
(en)
|
2003-08-18 |
2005-03-10 |
Macrogenics, Inc. |
FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
AU2004297616B2
(en)
|
2003-12-04 |
2008-12-18 |
Xencor, Inc. |
Methods of generating variant proteins with increased host string content and compositions thereof
|
|
US20050266425A1
(en)
*
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
CA2565874C
(en)
|
2004-05-10 |
2017-10-03 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
EP2471813B1
(en)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimized Fc variants
|
|
EP1778726A4
(en)
|
2004-08-16 |
2009-03-18 |
Medimmune Inc |
INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
WO2006105338A2
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
|
US8008443B2
(en)
|
2005-04-26 |
2011-08-30 |
Medimmune, Llc |
Modulation of antibody effector function by hinge domain engineering
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
WO2007008943A2
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
|
PL2573114T3
(pl)
|
2005-08-10 |
2016-10-31 |
|
Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
|
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
WO2007044616A2
(en)
|
2005-10-06 |
2007-04-19 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
KR20140133958A
(ko)
|
2005-10-21 |
2014-11-20 |
엘에프비 유에스에이, 인크. |
항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
|
|
JP5399712B2
(ja)
|
2005-12-21 |
2014-01-29 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
可溶性ｃｅａに対する抵抗性を有する医薬組成物
|
|
EP1999470A4
(en)
|
2006-03-10 |
2009-08-19 |
Macrogenics Inc |
IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
|
|
IL177158A0
(en)
|
2006-07-30 |
2008-01-20 |
Assaf Klar |
Method for designing and implementing improved longitudinal flexibility multilayered pipeline
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
|
WO2008121160A2
(en)
|
2006-11-21 |
2008-10-09 |
Xencor, Inc. |
Optimized antibodies that target cd5
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
WO2008091798A2
(en)
|
2007-01-22 |
2008-07-31 |
Xencor, Inc. |
Optimized ca9 antibodies and methods of using the same
|
|
EP2125893A2
(en)
|
2007-01-23 |
2009-12-02 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
WO2008098115A2
(en)
|
2007-02-07 |
2008-08-14 |
Xencor, Inc. |
Optimized igf-1r antibodies and methods of using the same
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
MX2009010611A
(es)
|
2007-04-03 |
2010-03-26 |
Micromet Ag |
Enlazadores biespecificos, especificos para especies.
|
|
RU2769948C2
(ru)
|
2007-04-03 |
2022-04-11 |
Эмджен Рисерч (Мьюник) Гмбх |
CD3-Эпсилон-связывающий домен с межвидовой специфичностью
|
|
EP2176298B1
(en)
|
2007-05-30 |
2017-11-15 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
CN101970499B
(zh)
|
2008-02-11 |
2014-12-31 |
治疗科技公司 |
用于肿瘤治疗的单克隆抗体
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
WO2009135181A2
(en)
|
2008-05-02 |
2009-11-05 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
BRPI0918670B8
(pt)
|
2008-09-17 |
2021-05-25 |
Xencor Inc |
anticorpo
|
|
DK2352763T4
(da)
|
2008-10-01 |
2022-10-17 |
Amgen Res Munich Gmbh |
Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
|
|
EP2352765B1
(en)
|
2008-10-01 |
2018-01-03 |
Amgen Research (Munich) GmbH |
Cross-species-specific single domain bispecific single chain antibody
|
|
US20110293619A1
(en)
|
2008-10-01 |
2011-12-01 |
Micromet Ag |
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
CN103261220B
(zh)
|
2010-08-16 |
2016-06-15 |
诺夫免疫股份有限公司 |
用于生成多特异性和多价抗体的方法
|
|
PE20141017A1
(es)
|
2011-03-02 |
2014-08-25 |
Roche Glycart Ag |
Anticuerpos del cea
|
|
US20140242081A1
(en)
|
2011-07-18 |
2014-08-28 |
Micromet Ag |
Dosing regimens for treatment of cea-expressing cancers
|
|
MX368257B
(es)
|
2011-08-01 |
2019-09-26 |
Genentech Inc |
Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
|
|
PT2768857T
(pt)
|
2011-10-19 |
2020-01-27 |
Novimmune Sa |
Métodos para purificar anticorpos
|
|
US20140140989A1
(en)
|
2012-02-06 |
2014-05-22 |
Inhibrx Llc |
Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
RU2015117393A
(ru)
*
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
|
DK3199552T3
(da)
|
2012-11-20 |
2020-03-30 |
Sanofi Sa |
Anti-ceacam5-antistoffer og anvendelser heraf
|
|
DK3725807T3
(da)
|
2012-12-03 |
2026-01-12 |
Novimmune Sa |
Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
LT2961771T
(lt)
|
2013-02-26 |
2020-03-10 |
Roche Glycart Ag |
Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
|
|
JP6843611B2
(ja)
|
2013-04-29 |
2021-03-17 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
免疫を強化する抗ｃｄ４７因子の使用
|
|
AU2014309199B2
(en)
|
2013-08-20 |
2018-04-19 |
Merck Sharp & Dohme Llc |
Treating cancer with a combination of a PD-1 antagonist and dinaciclib
|
|
CN106456748A
(zh)
|
2014-01-08 |
2017-02-22 |
小利兰·斯坦福大学托管委员会 |
小细胞肺癌的靶向疗法
|
|
CA2936244A1
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
|
RU2715038C2
(ru)
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Антитела анти-pd-l1 и способы их диагностического применения
|
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
TWI595006B
(zh)
*
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
RU2689689C2
(ru)
|
2015-01-23 |
2019-05-28 |
Хеликс Байофарма Корпорейшн |
Конъюгаты антитело-уреаза для терапевтических целей
|
|
PE20171790A1
(es)
*
|
2015-03-23 |
2017-12-28 |
Bayer Pharma AG |
Anticuerpos anti-ceacam6 y sus usos
|
|
PT3277821T
(pt)
|
2015-03-31 |
2019-10-31 |
Novimmune Sa |
Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos
|
|
DE102015212888A1
(de)
|
2015-07-09 |
2017-01-12 |
BSH Hausgeräte GmbH |
Geschirrspülmaschine mit einer Trocknungseinrichtung
|
|
AU2016304794B2
(en)
*
|
2015-08-07 |
2021-07-15 |
ALX Oncology Inc. |
Constructs having a SIRP-alpha domain or variant thereof
|
|
PE20180484A1
(es)
|
2015-10-02 |
2018-03-07 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
|
EP3165536A1
(en)
|
2015-11-09 |
2017-05-10 |
Ludwig-Maximilians-Universität München |
Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
|
|
GB2546072B
(en)
|
2016-01-05 |
2019-07-10 |
Bja Trading Ltd |
Attachment assembly and method of using same
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
PT3402820T
(pt)
*
|
2016-01-11 |
2020-08-20 |
Forty Seven Inc |
Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados
|
|
EP3454900A4
(en)
|
2016-05-09 |
2020-01-29 |
Celgene Corporation |
CD47 ANTIBODIES AND METHODS OF USE
|
|
CN107556386A
(zh)
*
|
2016-06-30 |
2018-01-09 |
中国科学院深圳先进技术研究院 |
抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
|
|
GB201611530D0
(en)
*
|
2016-07-01 |
2016-08-17 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
WO2018098384A1
(en)
*
|
2016-11-22 |
2018-05-31 |
Regents Of The University Of California |
Segregation modulation for immunotherapy
|
|
EP3802599B1
(en)
*
|
2018-06-03 |
2023-12-20 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
HRP20240213T1
(hr)
*
|
2020-12-18 |
2024-04-26 |
Lamkap Bio Beta Ag |
Bispecifična antitijela protiv ceacam5 i cd47
|